There has been increased bipartisan support around the expanded role of value-based insurance design.
This article was collaboratively written by A. Mark Fendrick, MD, director of the V-BID Center, and several V-BID Center staff.
On Thursday, October 27, 2016, the Senate Finance Committee Chronic Care Working Group released a discussion draft outlining bipartisan proposals on how to improve the health outcomes of Medicare beneficiaries living with chronic conditions. One section recommended the expansion of the Medicare Advantage (MA) Value-Based Insurance Design (VBID) demonstration plans to all 50 states.
This increased bipartisan support and expanded role of VBID principles in public and private payers builds on H.R. 5652 “Access to Better Care Act of 2016.” This bipartisan bill provides high-deductible health plans the flexibility to provide coverage for services that manage chronic disease prior to meeting the plan deductible.
This support is based off a growing body of evidence demonstrating that increases in patient cost sharing lead to decreases in the use of both nonessential and essential care. Medicare beneficiaries, many of whom manage multiple chronic conditions, are particularly at risk. Due to misaligned incentives, Medicare beneficiaries receive too much low-value care and too little high-value care.
Applying clinically nuanced VBID strategies presents an enormous opportunity for the Medicare program—particularly MA plans. A review of the peer-reviewed literature reveals how increases in Medicare beneficiary cost-sharing are adversely affecting our most vulnerable beneficiaries, contributing to poor patient-centered outcomes, and, in some instances, increasing Medicare expenditures. Actuarial modeling of MA-VBID programs for diabetes, chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF) demonstrates that consumer out-of-pocket costs are reduced in all 3 conditions, plan costs increase slightly in the short term for certain conditions (diabetes and COPD), and plan savings result for CHF. From the societal perspective, the diabetes program was close to cost neutral; net savings resulted in the COPD and CHF programs.
VBID can encourage the utilization of high-value providers and services and limit the use of services that are of potentially low-value, thus helping MA plans improve health and quality, enhance consumer engagement, and reduce costs.
To learn more about how VBID can play a role in Medicare Advantage, view the infographic below, and visit the Medicare and MA initiative page.
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen